| ²é¿´: 782 | »Ø¸´: 0 | |||
[½»Á÷]
¸÷ÖÖ¼²²¡×ÛºÏÕ÷
|
|
¿´ÎÄÏ×µÄʱºò×ÜÊÇ»áÓöµ½¸÷ÖÖ¼²²¡×ÛºÏÕ÷£¬Ã¿´Î¶¼µÃÏÖÈ¥²éÕÒ£¬Õâ´Î×ö¸öС×Ü½á£¬Ç°Ãæ¼¸¸ö¶¼ÊÇÕª×ÔÑîѧ¾üÏÈÉúµÄһƪÎÄÕ£¬ºóÃæµÄ¼¸¸öÊÇÎÒ×Ô¼º×ܽáµÄ¡£Ï£ÍûÄܸøÍ¬Ö¾ÃÇÒ»µã°ïÖú¡£ 1. IÐÍÉñ¾ÏËάÁö²¡£¨nerofibromatosis I NF1£©£ºNF1»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷ÊǶ෢Éñ¾ÏËάÁö¡¢¶ñÐÔÍâÖÜÉñ¾ÇÊÁö¡¢ÊÓÉñ¾½ºÖÊÁöºÍÆäËûÐÇÐÎϸ°ûÁö¡¢Æ¤·ô¶à·¢Å£ÄÌ¿§·È°ßºÍÒ¸ÎѼ°¸¹¹É¹µÈ¸°ß¡¢ºçĤ´í¹¹Áö£¨Lisch½á½Ú£©ºÍ¸÷ÖֹDz¡¡£ 2. IIÐÍÉñ¾ÏËάÁö²¡(nerofibromatosis II£ºNF2) NF2»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷±íÏÖΪÐíÍúϸ°ûÖ×ÁöÐÔ£¨ÐíÍúϸ°ûÁö£©ºÍ·¢Óý²»Á¼ÐÔ£¨Éñ¾Çʷʺñ²¡£©²¡±ä¡¢ÄÔĤϸ°û£¨ÄÔĤÁöºÍÄÔĤѪ¹ÜÁö²¡£©ºÍ½ºÖÊϸ°û£¨½ºÖÊÁöºÍ½ºÖÊ΢´í¹¹Áö£©²¡±ä¡¢Ë«²àǰͥÉñ¾ÐíÍúϸ°ûÁö¡¢ÒÔ¼°¾§ÌåºóÄÒ»ì×ǺÍÄÔ×éÖ¯¸Æ»¯¡£ 3. Von Hippel-Lindau£¨VHL£©²¡£ºVHL»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷ÊÇÖÐÊàÉñ¾ÏµÍ³ºÍÊÓÍøÄ¤Ñª¹Üĸϸ°ûÁö¡¢Éö͸Ã÷ϸ°û°©¡¢Êȸõϸ°ûÁö¡¢ÒÈÏÙºÍÄÚ¶úÖ×Áö¡£ 4. ½á½ÚÐÔÓ²»¯¸´Õ÷£¨tuberous sclerosis complex£¬TSC£©£ºTSC1»òTSC2»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷ÊÇÖÐÊàÉñ¾ÏµÍ³ºÍ¸÷ÖÖ·ÇÉñ¾×éÖ¯·¢Éú´í¹¹ÁöºÍÁ¼ÐÔÖ×Áö¡£Ö÷ÒªµÄÖÐÊàÉñ¾ÏµÍ³±íÏÖ,°üÀ¨Æ¤ÖÊ´í¹¹Áö¡¢Æ¤ÖÊϽºÖÊÉñ¾´í¹¹Áö¡¢ÊÒ¹ÜĤϽºÖʽá½ÚºÍÊÒ¹ÜĤϾÞϸ°ûÐÇÐÎϸ°ûÁö£¨subependymal giant cell astrocytoma£¬SEGA£©¡£Éñ¾ÏµÍ³ÒÔÍâ±íÏÖÓÐÆ¤·ôѪ¹ÜÏËάÁö¡¢öè¸ï°ß¡¢¼×ÖÜÏËάÁö¡¢ÉöѪ¹Ü¼¡Ö¬Áö¡¢ÄÚÔàÄÒÖס¢ÐÄÔàºáÎÆ¼¡Áö¡¢·ÎÁܰͼ¡¹ÜÁö¡£ 5. Li-Fraumeni×ÛºÏÕ÷£¨LFS£©£º¶àÊýÊÇÓÉTP53»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷ÊǶùͯºÍÄêÇáÈË·¢Éú¶à·¢µÄÔ·¢Ö×Áö£¬ÒÔÈí×éÖ¯ÈâÁö¡¢¹ÇÈâÁö¡¢ÈéÏÙ°©ÎªÖ÷£¬ÄÔÖ×Áö¡¢°×Ѫ²¡ºÍÉöÉÏÏÙÆ¤Öʰ©µÄ·¢ÉúÂÊÒ²³ÊÔö¼ÓÇ÷ÊÆ¡£ 6. Cowden²¡£¨CD£©£ºPTEN»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷ÊÇÒýÆð¶àÖÖ´í¹¹ÁöºÍÖ×Áö¡£Ð¡ÄÔµÄÅßÌ¥·¢Óý²»Á¼ÐÔÉñ¾½Úϸ°ûÁö£¨Lhermitte-Duclos²¡£©ÊÇÖ÷ÒªµÄÖÐÊàÉñ¾ÏµÍ³±íÏÖ¡£Éñ¾ÏµÍ³Íâ±íÏÖ°üÀ¨Æ¤·ôðà¡¢¿ÚǻճĤµÄÂÑʯÑùÇðÕîºÍÏËάÁö¡¢¶à·¢Ã沿ë¸ùÇÊÁö¡¢½á³¦´í¹¹ÁöÐÔÏ¢ÈâºÍÈéÏÙ°©¡£ 7. Turcot×ÛºÏÖ¢£º³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷Êǽ᳦ÏÙÁöÐÔÏ¢ÈⲡºÍ£¨»ò£©½á³¦°©Óë¶ñÐÔ¶ñÐÔÉñ¾ÉÏÆ¤Ö×Áö¹²»¼²¡¡£IÐÍΪDNA´íÅäÐÞ¸´»ùÒòÖÖϵͻ±äÒýÆð£¬ÒÅ´«ÐÔ·ÇÏ¢ÈⲡÐԽ᳦°©£¨hereditary nonpolyposis colon cancer,HNPCC£©°é·¢½ºÖÊĸϸ°ûÁö£»IIÐÍΪAPC»ùÒòÖÖϵͻ±äÒýÆð¼Ò×åÐÔÏÙÁöÐÔÏ¢Èⲡ(familial adenomatous polyposis£¬FAP)°é·¢Ëèĸϸ°ûÁö¡£ 8. Gorlin×ÛºÏÕ÷£ºPTCH»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷Êǹ㷺µÄ·¢ÓýÒì³£ºÍ°é·¢Á¼ÐԺͶñÐÔÖ×Áö¡£Ö÷ÒªÁÙ´²±íÏÖ°üÀ¨¶à·¢Æ¤·ô»ùµ×ϸ°û°©¡¢ÑÀÔ´ÐԽǻ¯ÄÒÖס¢ÕÆõÅÆ¤·ô°¼Ëð£¬ÒÔ¼°ÖÐÊàÉñ¾ÏµÍ³·¢ÉúÂÄڸƻ¯¡¢¾ÞÂÖ¢¡¢Ëèĸϸ°ûÁö 9. ÁÖÆæ×ÛºÏÕ÷£ºÁÖÆæ×ÛºÏÕ÷ÊÇ×î³£¼ûµÄÒ»ÖÖÒÅ´«ÐÔ½áÖ±³¦°©×ÛºÏÕ÷,Õ¼½áÖ±³¦°©µÄ2%¡«5%¡£ÁÖÆæ×ÛºÏÕ÷Ö¸µÄÊÇÄÇЩ¾ßÓдíÅäÐÞ¸´»ùÒò(MMR)Í»±äµ¼ÖÂÒ×»¼½áÖ±³¦°©ºÍÆäËû¶ñÐÔÖ×ÁöµÄ¸öÌå,°üÀ¨ÄÇЩÒѾ»¼ÓÐÖ×ÁöºÍÉÐδ·¢ÉúÖ×ÁöµÄÈËLynch syndrome is the most common cause of inherited colorectal cancer (CRC) and is due to germline mutations in mismatch repair (MMR) genes. Early Lynch syndrome diagnosis and appropriate CRC surveillance improves mortality. Traditional qualitative clinical criteria including Amsterdam and Bethesda guidelines may miss mutation carriers. 10. Li-Fraumeni×ÛºÏÕ÷£¨LFS£©£º¶àÊýÊÇÓÉTP53»ùÒòÖÖϵͻ±äÒýÆðµÄ³£È¾É«ÌåÏÔÐÔÒÅ´«²¡£¬ÌØÕ÷ÊǶùͯºÍÄêÇáÈË·¢Éú¶à·¢µÄÔ·¢Ö×Áö£¬ÒÔÈí×éÖ¯ÈâÁö¡¢¹ÇÈâÁö¡¢ÈéÏÙ°©ÎªÖ÷£¬ÄÔÖ×Áö¡¢°×Ѫ²¡ºÍÉöÉÏÏÙÆ¤Öʰ©µÄ·¢ÉúÂÊÒ²³ÊÔö¼ÓÇ÷ÊÆ LFS is a rare autosomal hereditary cancer syndrome characterized by a combination of tumors, predominantly sarcomas, breast cancers, brain tumors, andadrenocortical carcinomas (Olivier et al. 2003). Other less-common cancers have also been associated with LFS, including leukemia, lung cancers, melanoma, gastric cancers, pancreatic cancer, and prostate cancer(Olivier et al. 2003; Birch et al. 2001). According to the IARC (International Agency for Research on Cancer) database, gastric cancer has been reported in up to 2.8% of LFS families (Olivier et al. 2003). With this low frequency of gastric cancers in LFS, it is easy to overlook the possibility of LFS in families that appear to segregate gastric cancer. TP53 germline mutations have been identified in about 70% (Olivier et al. 2003) of LFS patients; more than 70% of the mutations are missense mutations (Chompret 2002; Olivier et al. 2003), and up to 90% of the missense mutations are located in exons 5¨C8 (Chompret 2002), which is thought to comprise the DNA-binding domain. 11. Cowden×ÛºÏÕ÷(Cowden¡¯s syndrome)Óֳƶ෢ÐÔ´í¹¹Áö×ÛºÏÕ÷£¬ÊÇÒ»ÖÖÉÙ¼ûµÄÒÅ´«ÐÔ¼²²¡¡£´í¹¹ÁöÕâÒ»ÊõÓïÊÇ1904ÄêÓÉAlbrechtÊ×´ÎʹÓã¬Òâ˼ÊÇÔÚ·¢ÓýÖгöÏÖ´íÎó¶øÐγɵÄÖ×Áö¡£´ËÖÖÏ¢Èâ¿ÉÒÔÊÇÕý³£×éÖ¯µÄÒì¹¹ÏÖÏó£¬ÓÐÒ»ÖÖ»ò¼¸ÖÖ×éÖ¯¹ý¶ÈÉú³¤µÄÖ×Áö¡£ThomsonµÈÈËÈÏΪ£¬´í¹¹ÁöÊÇ·ÇÖ×ÁöÐÔ¾ÖÏÞÐÔÖ×ÁöÑùÔöÉú£¬°üÀ¨ÒÔÒì³£ºÍÎÉÂÒ·½Ê½ÅÅÁеÄÕý³£×éÖ¯¡£±¾Õ÷Ϊ賦µÀ¶à·¢ÐÔÏ¢Èâ°éÓÐÃæ²¿Ð¡ÇðÕî¡¢Ö«¶Ë½Ç»¯²¡ºÍ¿ÚÇ»ð¤Ä¤ÈéÍ»Ñù²¡±ä¡£·¢²¡ÄêÁäΪ13¡«65Ë꣬ÒÔ25Ëêǰ¶à¼û£¬ÄÐŮ֮±ÈΪ1:1.5¡£±¾Õ÷ºÏ²¢¶ñÐÔÖ×ÁöµÄ·¢ÉúÂʸߴï40%£¬Ö÷ҪΪÈéÏÙ°©¡¢¼××´ÏÙ°©µÈ |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸±±»¯Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085601²ÄÁϹ¤³ÌÕÒµ÷¼Á
ÒѾÓÐ6È˻ظ´
318Ò»Ö¾Ô¸¼ªÁÖ´óѧÉúÎïÓëÒ½Ò© Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
һ־Ը˫һÁ÷»úе285·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸Ö£ÖÝ´óѧ£¬080500ѧ˶£¬×Ü·Ö317·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸Î人Àí¹¤£¬×Ü·Ö321£¬Ó¢Ò»Êý¶þ£¬ÇóÀÏʦÊÕÁô¡£
ÒѾÓÐ8È˻ظ´
375Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
ÄϾ©´óѧ»¯Ñ§µ÷¼Á
ÒѾÓÐ7È˻ظ´
070300»¯Ñ§354Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´














»Ø¸´´ËÂ¥
5